Table 4. Clinical characterization of CPP-Jardinópolis patients regarding the percentage of positivity to the clinical criteria used for the diagnosis of leprosy (n = 34) and data about BCG scar in Non-leprosy group distributed according the anti-PGL-I results.

Clinical criteria	Yes (n = 34)	%	anti-PGL-I + (n = 15)	%	anti-PGL-I—(n = 19)	%	z	p
Dysesthesia hypochromic macular skin lesions	30	88.2	13	86.7	17	89.5	0.25	0.80
Tactile sensitivity	5	14.7	2	13.3	3	15.8	0.20	0.84
Tactile + pain sensitivities	6	17.6	5	33.3	1	5.3	2.13	0.03
Tactile + thermal sensitivities	2	5.9	2	13.3	0	0
Thermal + tactile + pain sensitivities	17	50.0	5	33.3	12	63.2	1.73	0.08
Dysesthetic areas (without cutaneous signs)	11	32.4	2	13.3	9	47.4	2.11	0.03
Tactile sensitivity	1	2.9	0	0	1	5.3
Tactile + pain sensitivities	1	2.9	0	0	1	5.3
Thermal + tactile + pain sensitivities	10	29.4	2	13.3	8	42.1	1.83	0.07
Localized irregular patches of circumscribed hair loss	25	73.5	12	80.0	13	68.4	0.76	0.45
Altered nerves on palpation (enlargement and/or pain and/or electric shock-like pain)	33	97.1	15	100	18	94.7	0.90	0.37
Endogenous histamine test
Incomplete	17	50	8	53.1	9	47.4	0.35	0.73
Not performed	17	50	8	53.1	9	47.4	0.35	0.73
Sweat test (alizarin test)
Hypohidrosis and/or anhidrosis in islets	4	11.8	1	6.67	3	15.8	0.82	0.41
Leprosy classification
Borderline	31	91.2	15	100	16	84.2	1.61	0.11
PNL	3	8.8	1	6.7	2	10.5	0.39	0.70
WHO operational criteria
Multibacillary	34	100	15	100	19	100	0.0	1.0
WHO impairment grading
Grade 0	9	28.1	4	26.7	5	26.3	0.01	0.99
Grade 1	20	62.5	9	60.0	11	57.9	0.12	0.90
Grade 2	3	0.9	1	6.7	2	10.5	0.39	0.70
Not evaluated	2	-	1	-	1	-
BCG scar
0	2	11.8	1	6.7	1	5.3	0.17	0,87
1	29	85.3	13	86.7	16	78.9	0.59	0.56
≥2	1	2.9	0	0	1	3.1
Not evaluated	2	-	1	-	1	-
BCG scar—NLG
0	80		20	10.3	60	7.5	1.77	0.08
1	899		171	87.7	728	90.4	2.38	0.02
≥2	21		4	2.0	17	2.1	0.16	0.87
Not evaluated	216	-	51	-	165	-

PNL: pure neural leprosy; WHO: World Health Organization.